Trial IPI-145-08

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial

Trial acronym

IPI-145-08

Full title

Eine randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie von IPI-145 in Kombination mit Rituximab vs. Rituximab bei Patienten mit zuvor behandeltem follikulärem Lymphom

EudraCT number

2013-002406-31

NCT number

NCT02204982

Responsible organization

Medizinische Klinik III, Telefon: 089440072551

Indications

Classification	Code	Description
ICD-10-GM	C82.-	Follikuläres Lymphom
-		Bloodcancer (leukemia, lymphoma)

Trial design

Trial type

Interventional

Blinding type

Double blinded

Phase

III

Status

Trial finished

Votes

Institutional review board - vote

Unknown

Initiiation & lock

Date of lock (planned / actual)

2017-03-31 / Unknown

Participants

	Function	Prename	Surname	Organization
	Principal Investigator	MARTIN	DREYLING	Keine Organisationseinheit angegeben
	Responsible contact	Marta	Illenyi	Keine Organisationseinheit angegeben